Trial Profile
[PMS] LINZESS Tablet 0.25mg Long-term Specified Drug Use-results Survey in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation (Excluding Constipation Due to Organic Diseases)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Jan 2022
Price :
$35
*
At a glance
- Drugs Linaclotide (Primary)
- Indications Constipation; Irritable bowel syndrome
- Focus Adverse reactions
- Sponsors Astellas Pharma
- 19 Jan 2022 Status changed from active, no longer recruiting to completed.
- 21 Feb 2021 Planned End Date changed from 1 Dec 2021 to 31 Dec 2021.
- 21 Feb 2021 Planned primary completion date changed from 1 Dec 2021 to 31 Dec 2021.